Summary

The global humanized mouse and rat model market is projected to reach USD 338 million by 2027 from USD 237 million in 2022, at a CAGR of 7.4% during the forecast period of 2022 to 2027. Currently, immunodeficient mice engrafted with functional human cells, genes, and tissues have emerged as an important tool for the preclinical study of human diseases. Medical testing is done on humanized models as their genetic, biological, and behavioural characteristics resemble those of humans. Also, several medical conditions of humans can be replicated in humanized models and this is promoting market growth. Along with this growth in the humanized mouse and rat model market can be attributed to increased demand for personalized medicine, growing support through investments and grants from the government and private sector, and growth in the number of R&D activities carried out by pharmaceutical and biotechnology companies is driving market growth.
Humanized Rat Model Market is expected to account for the second-largest share for by type segment.
Based on type, the humanized mouse and rat model market has been segmented into humanized mouse models and humanized rat models. In 2021, humanized rat model market accounted for the second largest share. The liver metabolism of rats (in terms of the number and type of liver enzymes) is similar to humans. It is also easy to surgically modify rats and collect samples. The other advantages of rat models include favourable absorption, ease of handling, ability to sustain more intense intravenous dosing, and larger tissue sample. These advantages of rat models over mouse models are encouraging the development of humanized rat models.
The Oncology segment accounted for the highest market share of the application segment in the humanized mouse and rat model market
Based on application, the humanized mouse and rat model market is segmented into oncology, immunology and infectious diseases, neuroscience, haematopoiesis, toxicology, and other applications. In 2021 Oncology application had the highest market share as humanized mouse models have significantly contributed to the understanding of cancer biology, as they are useful in validating gene functions, identifying novel cancer genes & tumor biomarkers, understanding the molecular and cellular mechanisms underlying in tumor initiation, and providing better clinical models to test novel therapeutic strategies.
Europe is the second largest region in the humanized mouse and rat model market
The humanized mouse and rat model market is segmented into North America, Europe, Asia Pacific, Latin America (LATAM) and Middle East and Africa (MEA). After North America, In Europe, the growing pharmaceutical R&D expenditure and growth in the pharmaceutical and biotechnology are major driver for high market share.

The primary interviews conducted for this report can be categorized as follows:

• By Respondent: Supply Side- 80% and Demand Side 20%
• By Designation: Managers- 55%, CXOs and Director level - 20%, and Executives - 25%
• By Region: North America -45%, Europe -30%, Asia-Pacific -20%, Latin America -3%, and Middle East and Africa – 2%


Prominent Players of the humanized mouse and rat model market are Charles River Laboratories International, Inc. (US), The Jackson Laboratory (JAX) (US), Taconic Biosciences, Inc. (US), Crown Bioscience (US), Envigo (US).

Research Coverage:
This report provides a detailed picture of the humanized mouse and rat model market. It aims at estimating the size and future growth potential of the market across different segments such as the type, application, end user and region. The report also includes an in-depth competitive analysis of the key market players along with their company profiles recent developments and key market strategies.

Key Benefits of Buying the Report:
The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall humanized mouse and rat model market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, challenges, trends, and opportunities.
 
The report provides insights on the following pointers:
• Analysis of key drivers (Increasing research activities using humanized models, Rising demand for personalized medicine, Continuous support and initiatives from government and private sectors
for cancer research, and Growing R&D activities in pharmaceutical and biotechnology sectors), restraint (High cost of custom humanized models, Laws and regulations for ethical use of animal models in research), opportunities (Rising demand for humanized PDX models, Emergence of CRISPR as a powerful tool in biomedical research, Rising demand for humanized rat models), challenges (Alternatives for animal testing, Limitations of humanized mouse models) are influencing the growth of humanized mouse and rat model market.
• Product Development/Innovation: Detailed insights on newly launched product, and technological assessment of the humanized mouse and rat model market.
• Market Development: Comprehensive information about lucrative markets – the report analyses the humanized mouse and rat model market across varied regions.
• Market Diversification: Exhaustive information about new product, untapped geographies, recent developments, and investments in the humanized mouse and rat model market.
• Competitive Assessment: In-depth assessment of market shares, growth strategies and service offerings of leading players like Charles River Laboratories International, Inc. (US), The Jackson Laboratory (JAX) (US), Taconic Biosciences, Inc. (US), Envigo (US), among others in the humanized mouse and rat model market. The report also helps stakeholders understand the pulse of humanized mouse and rat model market and provides them information on key market drivers, restraints, challenges, and opportunities.

ページTOPに戻る

Table of Contents

1 INTRODUCTION 20
1.1 STUDY OBJECTIVES 20
1.2 MARKET DEFINITION 20
1.2.1 INCLUSIONS AND EXCLUSIONS 21
1.3 MARKET SCOPE 21
1.3.1 MARKETS COVERED 21
1.3.2 YEARS CONSIDERED 22
1.4 CURRENCY CONSIDERED 22
1.5 LIMITATIONS 22
1.6 STAKEHOLDERS 23
1.7 SUMMARY OF CHANGES 23
2 RESEARCH METHODOLOGY 24
2.1 RESEARCH APPROACH 24
2.1.1 SECONDARY DATA 24
2.1.2 PRIMARY DATA 24
2.1.2.1 Breakdown of primary sources 25
FIGURE 1 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION 25
2.1.2.2 Key industry insights 26
2.2 MARKET SIZE ESTIMATION 26
FIGURE 2 MARKET SIZE ESTIMATION: SUPPLY-SIDE ANALYSIS 26
FIGURE 3 CAGR PROJECTIONS FROM ANALYSIS OF DEMAND-SIDE DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 27
FIGURE 4 HUMANIZED MOUSE AND RAT MODEL MARKET: FINAL CAGR PROJECTIONS 28
FIGURE 5 HUMANIZED MOUSE AND RAT MODEL MARKET: SEGMENTAL ASSESSMENT 28
2.3 MARKET BREAKDOWN AND DATA TRIANGULATION 29
FIGURE 6 DATA TRIANGULATION METHODOLOGY 30
2.4 MARKET RANKING ANALYSIS 30
2.5 RESEARCH ASSUMPTIONS 31
3 EXECUTIVE SUMMARY 32
FIGURE 7 HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2022 VS. 2027 (USD MILLION) 32
FIGURE 8 HUMANIZED MOUSE AND RAT MODEL MARKET, BY APPLICATION, 2022 VS. 2027 (USD MILLION) 33
FIGURE 9 HUMANIZED MOUSE AND RAT MODEL MARKET, BY END USER, 2022 VS. 2027 (USD MILLION) 34
FIGURE 10 REGIONAL SNAPSHOT OF HUMANIZED MOUSE AND RAT MODEL MARKET 35
4 PREMIUM INSIGHTS 36
4.1 HUMANIZED MOUSE AND RAT MODEL MARKET OVERVIEW 36
FIGURE 11 GROWING RESEARCH ACTIVITIES USING HUMANIZED MODELS TO DRIVE MARKET GROWTH 36
4.2 ASIA PACIFIC: HUMANIZED MOUSE AND RAT MODEL MARKET, BY END USER AND COUNTRY (2021) 37
FIGURE 12 PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES SEGMENT DOMINATED ASIA PACIFIC MARKET IN 2021 37
4.3 GEOGRAPHICAL SNAPSHOT OF HUMANIZED MOUSE AND RAT MODEL MARKET 38
FIGURE 13 INDIA TO WITNESS HIGHEST GROWTH RATE FROM 2022 TO 2027 38
4.4 HUMANIZED MOUSE AND RAT MODEL MARKET, BY REGION 38
FIGURE 14 NORTH AMERICA TO DOMINATE MARKET IN 2027 38
4.5 HUMANIZED MOUSE AND RAT MODEL MARKET: DEVELOPED VS. DEVELOPING MARKETS 39
FIGURE 15 DEVELOPING MARKETS TO REGISTER HIGHER GROWTH RATE DURING FORECAST PERIOD 39
5 MARKET OVERVIEW 40
5.1 INTRODUCTION 40
5.2 MARKET DYNAMICS 40
FIGURE 16 HUMANIZED MOUSE AND RAT MODEL MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 40
5.2.1 DRIVERS 41
5.2.1.1 Increasing research activities using humanized models 41
5.2.1.2 Rising demand for personalized medicine 41
5.2.1.3 Continuous support and initiatives from government and private sectors for cancer research 42
5.2.1.4 Growing R&D activities in pharmaceutical and biotechnology sectors 42
TABLE 1 NUMBER OF DRUGS IN DEVELOPMENT, BY DISEASE AREA (2020) 43
5.2.2 RESTRAINTS 43
5.2.2.1 High cost of custom humanized models 43
5.2.2.2 Laws and regulations for ethical use of animal models in research 43
5.2.3 OPPORTUNITIES 44
5.2.3.1 Rising demand for humanized PDX models 44
5.2.3.2 Emergence of CRISPR as a powerful tool in biomedical research 44
5.2.3.3 Rising demand for humanized rat models 45
5.2.4 CHALLENGES 45
5.2.4.1 Alternatives for animal testing 45
5.2.4.2 Limitations of humanized mouse models 46
5.3 REGULATORY ANALYSIS 46
5.3.1 NORTH AMERICA 46
5.3.2 EUROPE 47
5.3.3 ASIA PACIFIC 49
5.3.3.1 China 49
5.3.3.2 Japan 49
5.3.3.3 India 50
5.3.3.4 Australia 50
5.3.4 LATIN AMERICA 50
5.3.5 MIDDLE EAST & AFRICA 51
5.4 PRICING ANALYSIS 51
TABLE 2 PRICE OF HUMANIZED MOUSE MODELS (2022) 51
5.5 TECHNOLOGY ANALYSIS 51
5.6 VALUE CHAIN ANALYSIS 52
FIGURE 17 CREATION OF HUMANIZED MODELS—MAXIMUM VALUE IS ADDED DURING IMPLANTATION OF GRAFT/TUMOR CELLS IN IMMUNODEFICIENT MICE OR RATS 52
5.7 ECOSYSTEM ANALYSIS OF HUMANIZED MOUSE AND RAT MODEL MARKET 53
FIGURE 18 ECOSYSTEM ANALYSIS OF HUMANIZED MOUSE AND RAT MODEL MARKET 53
TABLE 3 SUPPLY CHAIN ECOSYSTEM 54
5.8 PORTER’S FIVE FORCES ANALYSIS 55
TABLE 4 HUMANIZED MOUSE AND RAT MODEL MARKET: PORTER’S FIVE FORCES ANALYSIS 55
5.8.1 THREAT OF NEW ENTRANTS 55
5.8.2 THREAT OF SUBSTITUTES 55
5.8.3 BARGAINING POWER OF BUYERS 55
5.8.4 BARGAINING POWER OF SUPPLIERS 55
5.8.5 INTENSITY OF COMPETITIVE RIVALRY 55
5.9 PATENT ANALYSIS 56
FIGURE 19 PATENT APPLICATIONS FOR HUMANIZED MOUSE MODEL MARKET, JANUARY 2013 –SEPTEMBER 2022 56
6 HUMANIZED MOUSE AND RAT MODEL MARKET, BY TYPE 57
6.1 INTRODUCTION 58
TABLE 5 HUMANIZED MOUSE AND RAT MODEL MARKET, BY TYPE, 2020–2027 (USD MILLION) 58
6.2 HUMANIZED MOUSE MODELS 58
TABLE 6 HUMANIZED MOUSE MODEL MARKET, BY TYPE, 2020–2027 (USD MILLION) 59
TABLE 7 HUMANIZED MOUSE MODEL MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 59
6.2.1 GENETIC HUMANIZED MOUSE MODELS 60
6.2.1.1 Genetic humanized mouse models segment to account for larger market share 60
TABLE 8 GENETIC HUMANIZED MOUSE MODELS MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 60
6.2.2 CELL-BASED HUMANIZED MOUSE MODELS 61
TABLE 9 CELL-BASED HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2020–2027 (USD MILLION) 61
TABLE 10 CELL-BASED HUMANIZED MOUSE MODELS MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 61
6.2.2.1 CD34 humanized mouse models 62
6.2.2.1.1 Increasing demand for stem cell therapy to drive market growth 62
TABLE 11 CD34 HUMANIZED MOUSE MODELS MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 63
6.2.2.2 PBMC humanized mouse models 63
6.2.2.2.1 Growing prevalence of infectious diseases to drive demand 63
TABLE 12 PBMC HUMANIZED MOUSE MODELS MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 64
6.2.2.3 BLT humanized mouse models 65
6.2.2.3.1 Increasing HIV cases to drive demand 65
TABLE 13 BLT HUMANIZED MOUSE MODELS MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 66
6.3 HUMANIZED RAT MODELS 66
6.3.1 LACK OF GERMLINE-COMPETENT RAT EMBRYONIC STEM CELL LINES AFFECTED ADOPTION OVER LAST TWO DECADES 66
TABLE 14 HUMANIZED RAT MODELS MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 67
7 HUMANIZED MOUSE AND RAT MODEL MARKET, BY APPLICATION 68
7.1 INTRODUCTION 69
TABLE 15 HUMANIZED MOUSE AND RAT MODEL MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 69
7.2 ONCOLOGY 70
7.2.1 INCREASING APPLICATIONS OF MOUSE MODELS IN CANCER STUDIES TO DRIVE GROWTH 70
TABLE 16 HUMANIZED MOUSE AND RAT MODEL MARKET FOR ONCOLOGY, BY COUNTRY, 2020–2027 (USD MILLION) 71
7.3 IMMUNOLOGY AND INFECTIOUS DISEASES 71
7.3.1 DEVELOPMENT OF ADVANCED MODELS FOR HUMAN IMMUNOLOGY STUDIES TO BOOST GROWTH 71
TABLE 17 HUMANIZED MOUSE AND RAT MODEL MARKET FOR IMMUNOLOGY AND INFECTIOUS DISEASES, BY COUNTRY, 2020–2027 (USD MILLION) 72
7.4 NEUROSCIENCE 73
7.4.1 INCREASING FOCUS ON HUMANIZED MOUSE MODEL DEVELOPMENT FOR CNS DISORDERS TO PROPEL GROWTH 73
TABLE 18 HUMANIZED MOUSE AND RAT MODEL MARKET FOR NEUROSCIENCE, BY COUNTRY, 2020–2027 (USD MILLION) 73
7.5 HEMATOPOIESIS 74
7.5.1 GROWING DEMAND FOR STEM CELL THERAPY TO PROPEL GROWTH 74
TABLE 19 HUMANIZED MOUSE AND RAT MODEL MARKET FOR HEMATOPOIESIS, BY COUNTRY, 2020–2027 (USD MILLION) 74
7.6 TOXICOLOGY 75
7.6.1 RISING NUMBER OF CLINICAL STUDIES TO DRIVE DEMAND 75
TABLE 20 HUMANIZED MOUSE AND RAT MODEL MARKET FOR TOXICOLOGY, BY COUNTRY, 2020–2027 (USD MILLION) 76
7.7 OTHER APPLICATIONS 76
TABLE 21 HUMANIZED MOUSE AND RAT MODEL MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION) 77
8 HUMANIZED MOUSE AND RAT MODEL MARKET, BY END USER 78
8.1 INTRODUCTION 79
TABLE 22 HUMANIZED MOUSE AND RAT MODEL MARKET, BY END USER, 2020–2027 (USD MILLION) 79
8.2 PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES 79
8.2.1 INCREASING R&D ON DRUG DEVELOPMENT TO DRIVE GROWTH 79
TABLE 23 HUMANIZED MOUSE AND RAT MODEL MARKET FOR PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2020–2027 (USD MILLION) 81
8.3 CONTRACT RESEARCH ORGANIZATIONS 81
8.3.1 RISING OUTSOURCING OF DRUG DISCOVERY SERVICES TO DRIVE GROWTH 81
TABLE 24 HUMANIZED MOUSE AND RAT MODEL MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2020–2027 (USD MILLION) 82
8.4 ACADEMIC AND RESEARCH INSTITUTIONS 83
8.4.1 INCREASING LIFE SCIENCE R&D EXPENDITURE TO DRIVE GROWTH 83
TABLE 25 HUMANIZED MOUSE AND RAT MODEL MARKET FOR ACADEMIC AND RESEARCH INSTITUTIONS, BY COUNTRY, 2020–2027 (USD MILLION) 84
9 HUMANIZED MOUSE AND RAT MODEL MARKET, BY REGION 85
9.1 INTRODUCTION 86
TABLE 26 HUMANIZED MOUSE AND RAT MODEL MARKET, BY REGION, 2020–2027 (USD MILLION) 86
9.2 NORTH AMERICA 86
FIGURE 20 NORTH AMERICA: HUMANIZED MOUSE AND RAT MODEL MARKET SNAPSHOT 87
TABLE 27 NORTH AMERICA: HUMANIZED MOUSE AND RAT MODEL MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 87
TABLE 28 NORTH AMERICA: HUMANIZED MOUSE AND RAT MODEL MARKET, BY TYPE, 2020–2027 (USD MILLION) 88
TABLE 29 NORTH AMERICA: HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2020–2027 (USD MILLION) 88
TABLE 30 NORTH AMERICA: CELL-BASED HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2020–2027 (USD MILLION) 88
TABLE 31 NORTH AMERICA: HUMANIZED MOUSE AND RAT MODEL MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 89
TABLE 32 NORTH AMERICA: HUMANIZED MOUSE AND RAT MODEL MARKET, BY END USER, 2020–2027 (USD MILLION) 89
9.2.1 US 89
9.2.1.1 US to dominate North American market 89
TABLE 33 US: HUMANIZED MOUSE AND RAT MODEL MARKET, BY TYPE, 2020–2027 (USD MILLION) 90
TABLE 34 US: HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2020–2027 (USD MILLION) 90
TABLE 35 US: CELL-BASED HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2020–2027 (USD MILLION) 91
TABLE 36 US: HUMANIZED MOUSE AND RAT MODEL MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 91
TABLE 37 US: HUMANIZED MOUSE AND RAT MODEL MARKET, BY END USER, 2020–2027 (USD MILLION) 91
9.2.2 CANADA 92
9.2.2.1 Government initiatives to drive market growth 92
TABLE 38 CANADA: HUMANIZED MOUSE AND RAT MODEL MARKET, BY TYPE, 2020–2027 (USD MILLION) 93
TABLE 39 CANADA: HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2020–2027 (USD MILLION) 93
TABLE 40 CANADA: CELL-BASED HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2020–2027 (USD MILLION) 93
TABLE 41 CANADA: HUMANIZED MOUSE AND RAT MODEL MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 94
TABLE 42 CANADA: HUMANIZED MOUSE AND RAT MODEL MARKET, BY END USER, 2020–2027 (USD MILLION) 94
9.3 EUROPE 95
TABLE 43 EUROPE: HUMANIZED MOUSE AND RAT MODEL MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 95
TABLE 44 EUROPE: HUMANIZED MOUSE AND RAT MODEL MARKET, BY TYPE, 2020–2027 (USD MILLION) 95
TABLE 45 EUROPE: HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2020–2027 (USD MILLION) 96
TABLE 46 EUROPE: CELL-BASED HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2020–2027 (USD MILLION) 96
TABLE 47 EUROPE: HUMANIZED MOUSE AND RAT MODEL MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 96
TABLE 48 EUROPE: HUMANIZED MOUSE AND RAT MODEL MARKET, BY END USER, 2020–2027 (USD MILLION) 97
9.3.1 GERMANY 97
9.3.1.1 Germany to account for largest share in European market 97
TABLE 49 GERMANY: HUMANIZED MOUSE AND RAT MODEL MARKET, BY TYPE, 2020–2027 (USD MILLION) 98
TABLE 50 GERMANY: HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2020–2027 (USD MILLION) 98
TABLE 51 GERMANY: CELL-BASED HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2020–2027 (USD MILLION) 98
TABLE 52 GERMANY: HUMANIZED MOUSE AND RAT MODEL MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 99
TABLE 53 GERMANY: HUMANIZED MOUSE AND RAT MODEL MARKET, BY END USER, 2020–2027 (USD MILLION) 99
9.3.2 UK 99
9.3.2.1 Increasing cancer research to drive growth 99
TABLE 54 UK: HUMANIZED MOUSE AND RAT MODEL MARKET, BY TYPE, 2020–2027 (USD MILLION) 100
TABLE 55 UK: HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2020–2027 (USD MILLION) 100
TABLE 56 UK: CELL-BASED HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2020–2027 (USD MILLION) 100
TABLE 57 UK: HUMANIZED MOUSE AND RAT MODEL MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 101
TABLE 58 UK: HUMANIZED MOUSE AND RAT MODEL MARKET, BY END USER, 2020–2027 (USD MILLION) 101
9.3.3 FRANCE 101
9.3.3.1 Increasing government funding for research and investments in genomics to drive growth 101
TABLE 59 FRANCE: HUMANIZED MOUSE AND RAT MODEL MARKET, BY TYPE, 2020–2027 (USD MILLION) 102
TABLE 60 FRANCE: HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2020–2027 (USD MILLION) 102
TABLE 61 FRANCE: CELL-BASED HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2020–2027 (USD MILLION) 102
TABLE 62 FRANCE: HUMANIZED MOUSE AND RAT MODEL MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 103
TABLE 63 FRANCE: HUMANIZED MOUSE AND RAT MODEL MARKET, BY END USER, 2020–2027 (USD MILLION) 103
9.3.4 ITALY 103
9.3.4.1 Increasing pharmaceutical production in Italy to drive growth 103
TABLE 64 ITALY: HUMANIZED MOUSE AND RAT MODEL MARKET, BY TYPE, 2020–2027 (USD MILLION) 104
TABLE 65 ITALY: HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2020–2027 (USD MILLION) 104
TABLE 66 ITALY: CELL-BASED HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2020–2027 (USD MILLION) 105
TABLE 67 ITALY: HUMANIZED MOUSE AND RAT MODEL MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 105
TABLE 68 ITALY: HUMANIZED MOUSE AND RAT MODEL MARKET, BY END USER, 2020–2027 (USD MILLION) 106
9.3.5 SPAIN 106
9.3.5.1 Rising R&D expenditure to boost growth 106
TABLE 69 SPAIN: HUMANIZED MOUSE AND RAT MODEL MARKET, BY TYPE, 2020–2027 (USD MILLION) 106
TABLE 70 SPAIN: HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2020–2027 (USD MILLION) 107
TABLE 71 SPAIN: CELL-BASED HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2020–2027 (USD MILLION) 107
TABLE 72 SPAIN: HUMANIZED MOUSE AND RAT MODEL MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 107
TABLE 73 SPAIN: HUMANIZED MOUSE AND RAT MODEL MARKET, BY END USER, 2020–2027 (USD MILLION) 108
9.3.6 REST OF EUROPE 108
TABLE 74 ROE: HUMANIZED MOUSE AND RAT MODEL MARKET, BY TYPE, 2020–2027 (USD MILLION) 109
TABLE 75 ROE: HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2020–2027 (USD MILLION) 109
TABLE 76 ROE: CELL-BASED HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2020–2027 (USD MILLION) 109
TABLE 77 ROE: HUMANIZED MOUSE AND RAT MODEL MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 110
TABLE 78 ROE: HUMANIZED MOUSE AND RAT MODEL MARKET, BY END USER, 2020–2027 (USD MILLION) 110
9.4 ASIA PACIFIC 110
FIGURE 21 ASIA PACIFIC: HUMANIZED MOUSE AND RAT MODEL MARKET SNAPSHOT 111
TABLE 79 ASIA PACIFIC: HUMANIZED MOUSE AND RAT MODEL MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 112
TABLE 80 ASIA PACIFIC: HUMANIZED MOUSE AND RAT MODEL MARKET, BY TYPE, 2020–2027 (USD MILLION) 112
TABLE 81 ASIA PACIFIC: HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2020–2027 (USD MILLION) 112
TABLE 82 ASIA PACIFIC: CELL-BASED HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2020–2027 (USD MILLION) 113
TABLE 83 ASIA PACIFIC: HUMANIZED MOUSE AND RAT MODEL MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 113
TABLE 84 ASIA PACIFIC: HUMANIZED MOUSE AND RAT MODEL MARKET, BY END USER, 2020–2027 (USD MILLION) 114
9.4.1 CHINA 114
9.4.1.1 China to dominate Asia Pacific market 114
TABLE 85 CHINA: HUMANIZED MOUSE AND RAT MODEL MARKET, BY TYPE, 2020–2027 (USD MILLION) 115
TABLE 86 CHINA: HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2020–2027 (USD MILLION) 115
TABLE 87 CHINA: CELL-BASED HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2020–2027 (USD MILLION) 116
TABLE 88 CHINA: HUMANIZED MOUSE AND RAT MODEL MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 116
TABLE 89 CHINA: HUMANIZED MOUSE AND RAT MODEL MARKET, BY END USER, 2020–2027 (USD MILLION) 117
9.4.2 JAPAN 117
9.4.2.1 Growing research collaborations to drive market growth in Japan 117
TABLE 90 JAPAN: HUMANIZED MOUSE AND RAT MODEL MARKET, BY TYPE, 2020–2027 (USD MILLION) 118
TABLE 91 JAPAN: HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2020–2027 (USD MILLION) 118
TABLE 92 JAPAN: CELL-BASED HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2020–2027 (USD MILLION) 118
TABLE 93 JAPAN: HUMANIZED MOUSE AND RAT MODEL MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 119
TABLE 94 JAPAN: HUMANIZED MOUSE AND RAT MODEL MARKET, BY END USER, 2020–2027 (USD MILLION) 119
9.4.3 INDIA 119
9.4.3.1 Growing biotech industry in India to drive market growth 119
TABLE 95 INDIA: HUMANIZED MOUSE AND RAT MODEL MARKET, BY TYPE, 2020–2027 (USD MILLION) 120
TABLE 96 INDIA: HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2020–2027 (USD MILLION) 120
TABLE 97 INDIA: CELL-BASED HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2020–2027 (USD MILLION) 121
TABLE 98 INDIA: HUMANIZED MOUSE AND RAT MODEL MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 121
TABLE 99 INDIA: HUMANIZED MOUSE AND RAT MODEL MARKET, BY END USER, 2020–2027 (USD MILLION) 122
9.4.4 SOUTH KOREA 122
9.4.4.1 Growing efforts by government to drive market growth 122
TABLE 100 SOUTH KOREA: HUMANIZED MOUSE AND RAT MODEL MARKET, BY TYPE, 2020–2027 (USD MILLION) 123
TABLE 101 SOUTH KOREA: HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2020–2027 (USD MILLION) 123
TABLE 102 SOUTH KOREA: CELL-BASED HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2020–2027 (USD MILLION) 123
TABLE 103 SOUTH KOREA: HUMANIZED MOUSE AND RAT MODEL MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 124
TABLE 104 SOUTH KOREA: HUMANIZED MOUSE AND RAT MODEL MARKET, BY END USER, 2020–2027 (USD MILLION) 124
9.4.5 REST OF ASIA PACIFIC 124
TABLE 105 ROAPAC: HUMANIZED MOUSE AND RAT MODEL MARKET, BY TYPE, 2020–2027 (USD MILLION) 125
TABLE 106 ROAPAC: HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2020–2027 (USD MILLION) 125
TABLE 107 ROAPAC: CELL-BASED HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2020–2027 (USD MILLION) 126
TABLE 108 ROAPAC: HUMANIZED MOUSE AND RAT MODEL MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 126
TABLE 109 ROAPAC: HUMANIZED MOUSE AND RAT MODEL MARKET, BY END USER, 2020–2027 (USD MILLION) 127
9.5 LATIN AMERICA 127
9.5.1 INCREASING PHARMACEUTICAL R&D EXPENDITURE TO DRIVE MARKET GROWTH 127
TABLE 110 LATIN AMERICA: HUMANIZED MOUSE AND RAT MODEL MARKET, BY TYPE, 2020–2027 (USD MILLION) 128
TABLE 111 LATIN AMERICA: HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2020–2027 (USD MILLION) 128
TABLE 112 LATIN AMERICA: CELL-BASED HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2020–2027 (USD MILLION) 128
TABLE 113 LATIN AMERICA: HUMANIZED MOUSE AND RAT MODEL MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 129
TABLE 114 LATIN AMERICA: HUMANIZED MOUSE AND RAT MODEL MARKET, BY END USER, 2020–2027 (USD MILLION) 129
9.6 MIDDLE EAST & AFRICA 130
9.6.1 UAE HAS EMERGED AS KEY MARKET IN MEA REGION 130
TABLE 115 MIDDLE EAST & AFRICA: HUMANIZED MOUSE AND RAT MODEL MARKET, BY TYPE, 2020–2027 (USD MILLION) 130
TABLE 116 MIDDLE EAST & AFRICA: HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2020–2027 (USD MILLION) 131
TABLE 117 MIDDLE EAST & AFRICA: CELL-BASED HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2020–2027 (USD MILLION) 131
TABLE 118 MIDDLE EAST & AFRICA: HUMANIZED MOUSE AND RAT MODEL MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 131
TABLE 119 MIDDLE EAST & AFRICA: HUMANIZED MOUSE AND RAT MODEL MARKET, BY END USER, 2020–2027 (USD MILLION) 132
10 COMPETITIVE LANDSCAPE 133
10.1 OVERVIEW 133
10.2 KEY PLAYER STRATEGIES/RIGHT TO WIN 133
FIGURE 22 KEY DEVELOPMENTS IN HUMANIZED MOUSE AND RAT MODEL MARKET, 2019–2022 133
10.3 MARKET SHARE ANALYSIS 134
FIGURE 23 HUMANIZED MOUSE AND RAT MODEL MARKET SHARE, BY KEY PLAYER, 2021 134
TABLE 120 HUMANIZED MOUSE AND RAT MODEL MARKET: DEGREE OF COMPETITION 134
10.4 COMPANY EVALUATION MATRIX 135
10.4.1 STARS 135
10.4.2 EMERGING LEADERS 135
10.4.3 PERVASIVE PLAYERS 136
10.4.4 PARTICIPANTS 136
FIGURE 24 HUMANIZED MOUSE AND RAT MODEL MARKET: COMPANY EVALUATION MATRIX, 2021 136
10.5 COMPANY EVALUATION MATRIX: START-UPS/SMES 137
10.5.1 PROGRESSIVE COMPANIES 137
10.5.2 STARTING BLOCKS 137
10.5.3 RESPONSIVE COMPANIES 137
10.5.4 DYNAMIC COMPANIES 137
FIGURE 25 HUMANIZED MOUSE AND RAT MODEL MARKET: COMPANY EVALUATION MATRIX FOR START-UPS/SMES, 2021 138
10.6 FOOTPRINT ANALYSIS OF COMPANIES 139
10.6.1 PRODUCT FOOTPRINT OF COMPANIES 139
TABLE 121 PRODUCT FOOTPRINT OF COMPANIES: HUMANIZED MOUSE AND RAT MODEL MARKET (2021) 139
10.6.2 END-USER FOOTPRINT OF COMPANIES 140
TABLE 122 END-USER FOOTPRINT OF COMPANIES: HUMANIZED MOUSE AND RAT MODEL MARKET (2021) 140
10.6.3 REGIONAL FOOTPRINT OF COMPANIES 141
TABLE 123 REGIONAL FOOTPRINT OF COMPANIES: HUMANIZED MOUSE AND RAT MODEL MARKET (2021) 141
10.7 COMPETITIVE SCENARIO 141
TABLE 124 PRODUCT LAUNCHES 141
TABLE 125 DEALS 142
11 COMPANY PROFILES 143
11.1 KEY PLAYERS 143
(Business Overview, Products offered, Recent Developments, MnM View)*
11.1.1 CHARLES RIVER LABORATORIES INTERNATIONAL, INC. 143
TABLE 126 CHARLES RIVER LABORATORIES INTERNATIONAL, INC.: BUSINESS OVERVIEW 143
FIGURE 26 CHARLES RIVER LABORATORIES INTERNATIONAL, INC.: COMPANY SNAPSHOT (2021) 144
11.1.2 THE JACKSON LABORATORY 147
TABLE 127 THE JACKSON LABORATORY: BUSINESS OVERVIEW 147
FIGURE 27 THE JACKSON LABORATORY: COMPANY SNAPSHOT (2021) 147
11.1.3 TACONIC BIOSCIENCES, INC. 150
TABLE 128 TACONIC BIOSCIENCES, INC.: BUSINESS OVERVIEW 150
11.1.4 CROWN BIOSCIENCE 152
TABLE 129 CROWN BIOSCIENCE: BUSINESS OVERVIEW 152
11.1.5 CHAMPIONS ONCOLOGY, INC. 154
TABLE 130 CHAMPIONS ONCOLOGY: BUSINESS OVERVIEW 154
FIGURE 28 CHAMPIONS ONCOLOGY: COMPANY SNAPSHOT (2022) 154
11.1.6 INOTIV 156
TABLE 131 INOTIV: BUSINESS OVERVIEW 156
FIGURE 29 INOTIV: COMPANY SNAPSHOT 157
11.1.7 HERA BIOLABS 160
TABLE 132 HERA BIOLABS: BUSINESS OVERVIEW 160
11.1.8 GENOWAY 161
TABLE 133 GENOWAY: BUSINESS OVERVIEW 161
11.1.9 BEIJING VITALSTAR BIOTECHNOLOGY CO. LTD. 162
TABLE 134 VITALSTAR BIOTECHNOLOGY: BUSINESS OVERVIEW 162
11.1.10 INGENIOUS TARGETING LABORATORY 163
TABLE 135 INGENIOUS TARGETING LABORATORY: BUSINESS OVERVIEW 163
11.1.11 AXENIS 164
TABLE 136 AXENIS: BUSINESS OVERVIEW 164
11.1.12 TRANS GENIC 165
TABLE 137 TRANS GENIC: BUSINESS OVERVIEW 165
11.1.13 HARBOUR ANTIBODIES (A SUBSIDIARY OF HARBOUR BIOMED) 166
TABLE 138 HARBOUR ANTIBODIES: BUSINESS OVERVIEW 166
11.1.14 ONCODESIGN 167
TABLE 139 ONCODESIGN: BUSINESS OVERVIEW 167
11.1.15 PHARMATEST SERVICES 168
TABLE 140 PHARMATEST SERVICES: BUSINESS OVERVIEW 168
*Details on Business Overview, Products offered, Recent Developments, MnM View might not be captured in case of unlisted companies.
11.2 OTHER PLAYERS 169
11.2.1 OZGENE PTY LTD. 169
11.2.2 TRANSCURE BIOSERVICES 169
11.2.3 CYAGEN BIOSCIENCES 170
11.2.4 GVK BIO 170
11.2.5 BIOCYTOGEN 171
12 APPENDIX 172
12.1 DISCUSSION GUIDE 172
12.2 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 175
12.3 CUSTOMIZATION OPTIONS 177
12.4 RELATED REPORTS 177
12.5 AUTHOR DETAILS 178